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Abstract   
Tobacco smoking is a global health problem. The association of a functional common 
polymorphism in the catechol-o-methyltransferase gene (COMT val158met) with smoking 
behavior has been extensively studied, but with divergent findings. In the present study the 
frequency of COMT genotypes and alleles was evaluated in 578 male and a smaller group of 
79 female unrelated, medication-free Caucasian healthy subjects of Croatian origin. Smokers 
were classified as subjects smoking  10 cigarettes per day, while subjects who never smoked 
in their life were regarded as nonsmokers. A 2 test with standardized residuals and 
Bonferroni correction revealed significant (P=0.0017) differences in Met/Met, Met/Val or 
Val/Val genotype frequency between male smokers and nonsmokers. This significant 
association between COMT val158met polymorphism and smoking was not detected in 
female subjects, due to small number of women, which represents a limitation of the study. 
Our results confirmed the significant association between COMT variants and smoking, 
which was due to the higher frequency of Val/Val homozygotes in male smokers compared to 
male nonsmokers. These results suggest that carriers of high activity COMT variant are more 
prone to develop a higher level of nicotine dependence, or that they release more dopamine 
than carriers of Met/Met or Met/Val genotypes.  
Tobacco smoking is a global health problem with serious and far-reaching consequences 7. 
Substances from tobacco smoke may affect brain functions via several neurotransmitter 
systems 7. Smoking is related to different neuro-psychiatric disorders and altered behaviors, 
eliciting functional and structural changes in the brain, and might represent a risk factor for 
suicide 7.  Tobacco-related ailments, including heart diseases, pulmonary diseases, lung 
cancer and other malignancies, kill one in 10 adults 43. According to the report on global 
smoking statistics issued by WHO in 2002, smoking will kill one in six people by the year 
2030. One-third of adults in Croatia smoke, resulting in the smoking prevalence of 36%, 
which is higher than the respective prevalence of 33% in most European Union countries 22. 
The First Croatian Health Project showed that 34% of males and 27% of females smoke 
regularly 40. In addition, within the population of smokers in Croatia, 74% start smoking 
before the age of 20 40.  
 
Environmental, biological and genetic factors are involved in smoking behavior, smoking 
initiation, regular tobacco use, and nicotine dependence 15,19,27,38. Dopamine is a 
neurotransmitter important in mediating drug reward. Many different drugs have the ability to 
alter dopamine concentration in reward-relevant regions of the brain 17. Nicotine binds to 
nicotinic acetylcholine receptors in the brain and stimulates dopamine release and reuptake 
30. This leads to the increase in dopamine concentration 19. Dopaminergic system, as well 
as allelic variations in genes involved in the dopamine pathways, is considered the major risk 
factor for tobacco use and development of nicotine dependence 17. Candidate genes 
involved in nicotine dependence include genes for tyrosine hydroxylase (involved in 
dopamine synthesis), dopamine DRD1-DRD5 receptors; dopamine transporter (involved in 
dopamine reuptake), catechol-O-methyltransferase (COMT) and monoamine oxidase, and 
dopamine-beta-hydroxylase (enzymes for dopamine metabolism) 29,33.    
 COMT is an Mg2+-dependent enzyme responsible for degrading catecholamine 
neurotransmitters (dopamine, epinephrine, norepinephrine) 41. COMT converts dopamine 
into 3-methoxytyramine and norepinephrine into normetanephrine, by introducing a methyl 
group derived from S-adenosyl methionine to a hydroxyl group located on a catechol nucleus 
1. It has been associated with broad range of psychiatric disorders. COMT gene lies within 
the q11 band of human chromosome 22 12, and has two promoters, namely P1 and P2 36. 
The longer mRNA transcribed by initiation through P2 promoter encodes for membrane-
bound COMT (MB-COMT), and the transcription of shorter mRNA is directed by promoter 
P1 encoding for soluble COMT (S-COMT). The longer MB-COMT form is mainly expressed 
in brain neurons 24, and it has a higher affinity for the substrate, but a lower catalytic 
activity then the shorter form (S-COMT) 21. The most studied variation in the COMT gene 
is a single base pair substitution of guanine for adenine which alters a single protein building 
block (amino acid) in the enzyme, replacing the amino acid valine (Val) with methionine 
(Met) at position 158 (Val158Met) in the longer form of the enzyme (MB-COMT), and at 
position 108 (Val108Met) in the shorter form (S-COMT) 21. This Val108/158Met 
substitution or rs4680 is a functional polymorphism that affects COMT activity 16,21,42. 
The Val variant of COMT is a high (H) activity allele, and has a higher stability and activity, 
catabolizing dopamine up to four times the rate of its Met alternative (or the low activity (L) 
allele) 4,34,41.  
Several studies investigated the association between COMT Val158Met 
polymorphism and nicotine dependence with divergent findings. On one hand, no association 
between COMT polymorphism and smoking initiation, smoking persistence, or smoking 
cessation has been confirmed 6,11,25, while on the other hand, some studies show 
significant association between COMT Val158Met polymorphism and nicotine dependence 
2,13,32, or smoking cessation 5,28,29. Sex differences can be observed in the genetic 
origins of smoking 2,10,20, and in the association between COMT Val158Met genotype and 
smoking behavior 2,5. We tested the hypothesis that COMT Val158Met is associated with 
smoking in ethnically homogenous sample of healthy male and a smaller group of female 
Caucasian subjects of European ancestry, pertaining to Croatian origin. 
The study included 578 male and 79 female unrelated, medication-free Caucasian 
healthy subjects of Croatian origin, who were recruited in the period between 2006 and 2009 
at the University Hospital Centre Zagreb, Zagreb, Croatia, and who filled in the questionnaire 
answering the questions about their medical history, smoking and drinking habits. All subjects 
were categorized into smokers and nonsmokers, with smokers classified as subjects smoking 
 10 cigarettes per day, and nonsmokers classified as subjects who never smoked in their life. 
The average age of male and female subjects was 39.43511.771 and 43.03813.307 years, 
respectively. All individuals gave their detailed medical history. Inclusion criteria were no 
current medication therapy; no previous or current psychiatric disorders; no drug or alcohol 
abuse, nor suicidal attempts; no family history of psychiatric disorders (determined according 
to the answers of participants about the mental health status of their parents, grandparents, 
siblings and children); not being related; and belonging to the native ethnic group with at least 
three generations living in the region. Written informed consent was obtained from all 
participants, after explaining the aims and procedures of the study, under guidelines approved 
by the Ethics committee of the University Hospital Centre Zagreb, Zagreb, Croatia. All 
human studies have been executed with the full cooperation of participants, adequate 
understanding, and have therefore been performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki.  
Blood samples (8 ml) were drawn using plastic syringes with 2 ml of acid citrate dextrose 
anticoagulant at 08.00 h. Genomic DNA was extracted from peripheral blood using the salting 
out method 26. The COMT val158met polymorphisms was genotyped with the ABI Prism 
7000 Sequencing Detection System apparatus (ABI) using the Taqman-based allele-specific 
polymerase chain reaction assay, according to manufacturers instructions (Applied 
Biosystems, Foster City, CA, USA). The primers and probes were purchased from Applied 
Biosystems. The results were expressed as means ± standard deviations (S.D.) and evaluated 
with Sigma Stat 3.5 (Jandell Scientific Corp. San Raphael, California, USA) and Microsoft 
Excel. Differences in age were assessed using one-way analysis of variance (ANOVA). The 
Hardy-Weinberg analysis was used to test the equilibrium of the population. The differences 
in genotype and allele frequencies were evaluated using the 2 test, with standardized 
residuals (R) in each cell. Bonferroni correction, with the number of tests (N=2) as correction 
factor, was used, and the level of significance was set to α = 0.025.   
The genotype (Met/Met, Met/Val or Val/Val) distribution in male (2=0.068; d.f.=1; 
P=0.795) or female (2=0.293; d.f.=1; P=0.588) subjects, as well as in male smokers (2 
=3.450; d.f.=1; P=0.063) or male nonsmokers (2 =2.576; d.f.=1; P=0.108) did not deviate 
significantly from the expected Hardy–Weinberg equilibrium. The same distribution was 
observed in female smokers (2 =0.631; d.f.=1; P=0.426) or female nonsmokers (2 =1.142; 
d.f.=1; P=0.285). In line with previous findings 12,24, this equilibrium showed a marginal 
trend towards significance in male smokers. 
Due to the fact that gender-gene interaction significantly affects smoking behavior, 
and smoking was reported to be differently related with COMT val158met polymorphism in 
female and male subjects 2,5, the effect of smoking was evaluated separately in male and 
female subjects (Table 1).  
Within larger group of male smokers and nonsmokers (Table 1), significant difference 
was found in Met/Met, Met/Val and Val/Val genotype frequency, but not in Met or Val allele 
frequency. These differences were due to the higher frequency of Val/Val genotypes (32.8% 
vs. 22.6%) in male smokers compared to male nonsmokers. The highest R value of 1.85 was 
detected in Val/Val genotype in smokers, indicating significant association of the Val/Val 
genotype with smoking behavior in male subjects. In the smaller group of female smokers and 
nonsmokers (Table 1), there was no significant difference in genotype and allele frequency of 
the COMT val158met.  
Female nonsmokers were slightly older than male smokers, but this difference was not 
significant after the Bonferroni correction. Age of the other groups did not differ significantly 
(Table 1). There was no significant difference in age between groups of male (F=1.080; 
d.f.=5,572; P=0.371) and female (F=0.640; d.f.=5,73; P=0.670) healthy subjects subdivided 
according to smoking status and COMT genotype. 
The results of the present study indicate a significant association between smoking 
(smoking more than 10 cigarettes per day, versus never smoking) and COMT val158met 
polymorphism in large groups of male homogenous Caucasian individuals of Croatian origin. 
This strong association detected for Met/Met, Met/Val and Val/Val genotype frequency, 
significant even after a conservative Bonferroni correction, was due to the higher percent of 
Val/Val homozygotes in male smokers compared to male nonsmokers. The difference in 
genotype distribution was modest (a 10% difference between male nonsmokers and smokers), 
showing that Val/Val genotype occurs more frequently among male smokers than 
nonsmokers, and indicating its contribution to this significant association.  
Our results concur with the data showing an association between the Val/Val genotype 
and smoking at least one pack per day 37, Val allele and persistent smoking among women 
5, and Val allele and current smoking status 10. Additionaly, Val carriers were reported to 
relapse quicker into smoking in randomized treatment trials of smoking cessation 28. On the 
other hand, collective results of our study are in disagreement with previous findings 
exhibiting association of the low activity Met allele with nicotine dependence 2, or with the 
results indicating that one or more Met alleles may enhance the addictive power of nicotine 
32. Additionally, our data does not coincide with the finding that Met allele carriers had 
higher Fagerstrom Test for Nicotine Dependence and started to smoke earlier, indicating that 
COMT polymorphism influences smoking severity and age of onset, which was initially 
observed in Chinese male population 13. Finally, our findings are not in line with the results 
showing no association between COMT polymorphism and smoking initiation, smoking 
persistence, smoking cessation or smoking intensity 6,11,13,25,35.  
The positive association between Val/Val genotype and smoking, found in the present 
study, was not confirmed in female subjects due to the substantially smaller female sample 
size, presumably due to the type I error, which represents a limitation of the study. In contrast 
to our results, previous studies reported association of Met/Met genotype and higher 
probability of smoking cessation in women 5. The genetic origin of smoking, smoking 
initiation and smoking persistence is gender dependent 2,10,20, indicating that the COMT 
val158met polymorphism affects catecholaminergic systems differently in male and female 
patients. A possible explanation for this gender-specific association might be due to the effect 
of estrogen in females, which modulates neurotransmission and neuronal excitability of 
catecholaminergic systems 14, resulting in different levels of dopamine in the synapse and 
different influence of dopamine on emotion and motivation among men and women 7. In 
addition, it has been suggested that gender related differences in smoking behavior might be 
due to the fact that COMT val158met polymorphism may differently influence personality 
traits that presumably affect smoking behavior, and that Val/Val genotype may be related to 
higher novelty or risk seeking traits than carriers of other genotypes 7,10,39. Since no 
evaluation of personality traits in male subjects was performed in the present study, we can 
neither confirm nor exclude these presumptions. The data, showing increased tendency 
towards smoking in Val/Val male homozygotes, might be explained by the fact that these 
subjects, who have high activity COMT variant, are more prone to develop a higher level of 
dependence and are more predisposed to smoking relapse 5,31. This effect might be 
mediated by the lower concentration of frontocortical dopamine in carriers of the high activity 
COMT variant 9. Significant association between Val/Val genotype and smoking might also 
be due to the fact that the Val/Val genotype may represent a risk factor for altered brain 
function and cognition during nicotine abstinence, i.e. a risk factor for increased susceptibility 
to nicotine dependence and smoking relapse 23. In addition, carriers of Val/Val genotype 
were shown to have greater release of dopamine induced by smoking than carriers of Met/Met 
or Met/Val genotypes 3. 
In conclusion, the results of the study confirmed a significant association between 
COMT variants and smoking more than 10 cigarettes per day, compared to complete, life-
long abstinence from smoking in healthy male medication-free Caucasian healthy subjects. 
The observed association was due to the higher percent of Val/Val homozygotes in male 
smokers compared to male nonsmokers. 
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Table 1.  Age and the COMT genotype and allele number (N), frequencies (%), and 
standardized residuals (R) in male and female healthy subjects, subdivided according to the 
smoking status. 
 
 
N is the observed number of genotypes or alleles; % is the frequency of the genotypes or 
alleles; R represents the standardized residuals in each cell; NS = not significant   
 
 
 Healthy subjects (N=657) 
 Men Women 
 
 
Smokers 
N   (%)          R 
Nonsmokers 
N  (%)          R 
Smokers 
N   (%)        R 
Nonsmokers 
N   (%)          R 
Genotypes 
Met/Met 44 (24.4)     0.20  93  (23.4)    -0.14   3 (13.0)   -1.08 16 (28.6)   0.69 
Met/Val 77 (42.8)   -1.46 215 (54.0)     0.98 13 (56.5)     0.68 24 (42.8)  -0.44 
Val/Val 59 (32.8)     1.85  90  (22.6)    -1.24  7 (30.5)      0.12 16 (28.6)  -0.08 
χ2-test χ2 =8.130; d.f.=2; P=0.017 χ2 =2.318; d.f.=2; P=0.316; NS 
Alleles 
Met 165 (45.8)   -0.89 401 (50.4)      0.55  19 (41.3)   -0.71 56 (50.0)    0.32 
Val 195 (54.2)    0.79 395 (49.6)    -0.58 27 (58.7)    0.58  56 (50.0)  -0. 43 
χ2-test χ2=1.870;  d.f.=1; P=0.171; NS χ2=0.671;  d.f.=1; P=0.413; NS 
 
 Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Age (years) 37.82 11.00 42.30 12.54 40.15 12.04 43.34 13.71** 
ANOVA F=3.387; d.f.=3,653; P=0.018; **P=0.017 vs. male smokers 
